Patents by Inventor Ralf Mattes

Ralf Mattes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6352848
    Abstract: A novel rec-L-N-carbamoylase from Arthrobacter aurescens and its method of use for producing L-amino acids. The recombinantly produced L-carbamoylase is unexpectedly stable, so that an industrial method of producing L-amino acids can be established with it, in contrast to previously known L-carbamoylases.
    Type: Grant
    Filed: April 2, 1999
    Date of Patent: March 5, 2002
    Assignees: Degussa-Huls Aktiengesellschaft, Universitat Stuttgart, Roche Diagnostics GmbH
    Inventors: Josef Altenbuchner, Ralf Mattes, Markus Pietzsch, Christoph Syldatk, Anja Wiese, Burkard Wilms
  • Patent number: 6270988
    Abstract: The present invention provides a process for the expression of a recombinant gene, which contains AGA and/or AGG codons for arginine, in Escherichia coli after transformation with an expression vector which contains the recombinant gene, wherein the amount of t-RNA present in the E. coli cells which incorporates arginine and recognises the codons AGG and AGA is increased to at least fivefold of the amount normally occurring in these cells.
    Type: Grant
    Filed: January 27, 1993
    Date of Patent: August 7, 2001
    Assignee: Roche Diagnostics GmbH
    Inventors: Ulrich Brinkmann, Ralf Mattes, Stephan Fischer
  • Patent number: 5985622
    Abstract: The invention relates to sucrose isomerases, to DNA sequences coding therefor, and to novel processes for the production of non-cariogenic sugars.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: November 16, 1999
    Assignee: Sudzucker Aktiengesellschaft
    Inventors: Ralf Mattes, Kathrin Klein, Hubert Schiweck, Markwart Kunz, Mohammed Munir
  • Patent number: 5985668
    Abstract: The invention relates to sucrose isomerases, to DNA sequences coding therefor, and to novel processes for producing noncariogenic sugars.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: November 16, 1999
    Assignee: Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt
    Inventors: Ralf Mattes, Kathrin Klein, Sabine Stegmaier
  • Patent number: 5786140
    Abstract: The invention relates to sucrose isomerases, to DNA sequences coding therefor, and to novel processes for the production of non-cariogenic sugars.
    Type: Grant
    Filed: January 18, 1995
    Date of Patent: July 28, 1998
    Assignee: Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt
    Inventors: Ralf Mattes, Kathrin Klein, Hubert Schiweck, Markwart Kunz, Mohammad Munir
  • Patent number: 5702888
    Abstract: For the detection of nucleic acids of definite sequence by hybridisation with a complementary nucleic acid probe which contains bound via a chemical bonding at least one hapten as labelling one uses, as hapten, a steroid which is bound vie a bridge of at least 4 atoms length to at least one position of the nucleic acid probe which does not participate in hydrogen bridge formation and detects the hybridised probe via an in turn labelled anti-hapten antibody.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: December 30, 1997
    Assignee: Boehringer Mannheim GmbH
    Inventors: Hans-Joachim Holtke, Rudolf Seibl, Gudrun Schmitz, Hans Robert Scholer, Christoph Kessler, Ralf Mattes
  • Patent number: 5593865
    Abstract: A process for the activation of disulphide linked recombinant proteins expressed in prokaryotes is described. The process includes cell digestion, solubilization under denaturing and reducing conditions and activation under oxidizing conditions in the presence of GSH/GSSG and a non-denaturing amount of a denaturing agent.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: January 14, 1997
    Assignee: Boehringer Mannheim GmbH
    Inventors: Rainer Rudolph, Stephan Fischer, Ralf Mattes
  • Patent number: 5453363
    Abstract: A process for the activation of t-PA or IgG after expression in prokaryotes is described. The process includes cell digestion, solubilization under denaturing and reducing conditions and activation under oxidizing conditions in the presence of GSH/GSSG.
    Type: Grant
    Filed: March 2, 1994
    Date of Patent: September 26, 1995
    Assignee: Boehringer Mannheim GmbH
    Inventors: Rainer Rudolph, Stephan Fischer, Ralf Mattes
  • Patent number: 5354657
    Abstract: The present invention provides a process for the detection of nucleic acids of definite sequence by hybridisation with two single-stranded nucleic acid probes present in the same solution phase complementary to different regions of the nucleic acid to be detected, one nucleic acid probe serving as detector probe and containing as labelling at least one hapten bound via a chemical linkage and the other nucleic acid probe serving as capturing probe and being bound to a solid matrix, wherein, as hapten, a steroid is used which on at least one position of the detector probe, which does not participate in the hydrogen bridge formation with the nucleic acid to be detected, is covalently bound via a bridge of at least four atoms, the nucleic acid to be detected, present in solution, is incubated with the detector probe and the capturing probe in any desired sequence, whereby the binding of the capturing probe on the matrix with the nucleic acid to be detected is brought about before, during or after the incubation,
    Type: Grant
    Filed: December 18, 1992
    Date of Patent: October 11, 1994
    Inventors: Hans J. Holtke, Rudolf Seibl, Christoph Kessler, Ralf Mattes, Hermann Graf
  • Patent number: 5344757
    Abstract: For the detection of nucleic acids of definite sequence by hybridisation with a complementary nucleic acid probe which contains bound via a chemical bonding at least one hapten as labelling one uses, as hapten, a steroid which is bound via a bridge of at least 4 atoms length to at least one position of the nucleic acid probe which does not participate in hydrogen bridge formation and detects the hybridised probe via an in turn labelled anti-hapten antibody.
    Type: Grant
    Filed: January 9, 1990
    Date of Patent: September 6, 1994
    Assignee: Boehringer Mannheim GmbH
    Inventors: Hans-Joachim Holtke, Rudolf Seibl, Gudrun Schmitz, Hans R. Scholer, Christoph Kessler, Ralf Mattes
  • Patent number: 5336602
    Abstract: An expression enhancer has a DNA sequence which is capable of forming a t-RNA clover-leaf structure after transcription and hybridizes in that region of the DNA which, after transcription, forms the anticodon loop in the clover-leaf structure with an oligonucleotide with the sequence 5'-GACTTAGAAGGTCGTT-3' or its complementary sequence (5'-AACGACCTTCTAAGTC-3'). It can be used to increase the yield in the expression of a recombinant gene by transformation of suitable host cells with an expression vector containing the recombinant gene, whereby it is likewise introduced into the host cells in a form capable of expression and expressed.
    Type: Grant
    Filed: January 22, 1993
    Date of Patent: August 9, 1994
    Assignee: Boehringer Mannheim GmbH
    Inventors: Ulrich Brinkmann, Ralf Mattes, Peter Buckel
  • Patent number: 5061625
    Abstract: To prepare a microorganism producing .alpha.-galactosidase, not only a DNA containing an .alpha.-galactosidase gene but also a vector which is appropriate to the transformable cells to be used and contains antibiotic resistance genes are completely split with restriction endonuclease Sal I, the fragment of approximately four megadaltons of relative molecular weight is obtained from the fragments of the DNA containing the .alpha.-galactosidase gene, is mixed with the solution of the vector also split with Sal I, and is recombined in the presence of DNA ligase with the formation of a recombinant DNA.
    Type: Grant
    Filed: August 24, 1988
    Date of Patent: October 29, 1991
    Assignee: Boehringer Mannheim GmbH
    Inventors: Ralf Mattes, Klaus Beaucamp
  • Patent number: 4963469
    Abstract: The present invention provides an enzymatically-inactive, immunologically-active .beta.-galactosidase mutein, wherein, in the region between the amino acids 430 and 550, at least one amino acid of the natural sequence is changed to another amino acid and the enzymatic activity does not amount to more than 1%, referred to the native enzyme. The present invention also provides a process for the production of this mutein. Furthermore, the present invention is concerned with the use of this mutein in the immunological determination of serum proteins by the enzyme immunoassay principle.
    Type: Grant
    Filed: July 12, 1988
    Date of Patent: October 16, 1990
    Assignee: Boehringer Mannheim GmbH
    Inventors: Ralf Mattes, Helmut Lenz, Werner Stock